Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer

Outcomes for metastatic colorectal cancer (mCRC) patients have been improved by treatment with anti-epidermal growth factor receptor (anti-EGFR) antibodies, particularly when combined with predictive biomarkers to select patients lacking mutations. New technologies such as liquid biopsy and next-gen...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2017-04, Vol.18 (4), p.752-752
Main Authors: Miyamoto, Yuji, Suyama, Koichi, Baba, Hideo
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Biopsy
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Colorectal Neoplasms - metabolism
Drug Resistance, Neoplasm - genetics
Epidermal growth factor
Epidermal growth factor receptors
Growth factors
Humans
MAP kinase
Metastases
Metastasis
Molecular Targeted Therapy - methods
Molecular Targeted Therapy - trends
Mutation
Neoplasm Metastasis
New technology
Next-generation sequencing
Proto-Oncogene Proteins p21(ras) - antagonists & inhibitors
Proto-Oncogene Proteins p21(ras) - genetics
Proto-Oncogene Proteins p21(ras) - metabolism
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - genetics
Receptor, Epidermal Growth Factor - metabolism
Review
Signal transduction
Signal Transduction - drug effects
Signal Transduction - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Outcomes for metastatic colorectal cancer (mCRC) patients have been improved by treatment with anti-epidermal growth factor receptor (anti-EGFR) antibodies, particularly when combined with predictive biomarkers to select patients lacking mutations. New technologies such as liquid biopsy and next-generation sequencing have revealed that potential mechanisms of resistance to anti-EGFR therapies act through acquired mutations of and the ectodomain. Mutations in cross-talking molecular effectors that participate in downstream EGFR signaling are also negative predictors for anti-EGFR therapy. In the current review, we describe recent advances in anti-EGFR therapy and discuss new treatment strategies to target downstream RAS-MAPK signaling in mCRC.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms18040752